Expression of Annexin Al and KI-67 in histopathologically negative margins of oral squamous cell carcinoma cases with and without local recurrence by Maheswari, U
Scanned by CamScanner
Scanned by CamScanner
Scanned by CamScanner
Scanned by CamScanner
Scanned by CamScanner
Scanned by CamScanner
ACKNOWLEDGEMENT 
I thank GOD ALMIGHTY, from whom I receive everything for 
accomplishing my desires. He made many impossible things possible in my life. 
  I am much obliged and I would like to extend my heartfelt gratitude to                                   
Dr.(Capt.)S.Gokulanathan B.Sc, M.D.S., Dean, Vivekanandha Dental College for 
Women, for permitting me to pursue this study. 
My sincere thanks and deep sense of gratitude to Dr.N.Balan M.D.S., 
Principal, Vivekanandha Dental College for Women, for his kindness in allowing me 
to utilize the facilities in the college. 
With submissive ambition, I aspire to register my gratitude to my respected 
Head of the Department, my mentor and guide, Professor Dr.N.Ganapathy M.D.S., 
Department of Oral Pathology & Microbiology, Vivekananda Dental College for 
Women for his inspiring guidance, invaluable counsel and encouragement throughout 
the course of the study. This work would not have seen the light of the day without his 
ability to understand the students with compassionate counseling which reposed by 
confidence in myself to undertake the challenges in the study. 
I express my deep sense of gratitude to senior Lecturer                          
Dr.A.Yamuna Devi M.D.S., who always supports me with smiling face and 
encouragement. Her valuable suggestions and generous support rendered throughout 
my course. 
I owe my thanks and great honour to my Associate professors                           
Dr.T.Maheswaran M.D.S, Dr.V.Ilayaraja M.D.S, Dr.T.R. Yoithap Prabhunath 
M.D.S, Dr.J.Dinesh Shankar M.D.S and Senior Lecturer Dr.P.Tamil Thangam 
M.D.S, for the encouragement and the help to enrich my knowledge throughout my 
study period. 
I thank Mr. Nitin Ramesh Pardule, for supporting me throughout my study. 
I thank Dr. Nandakumar, for helping me with the statistics in the study. 
I acknowledge my batch mates Dr. T. KeerthiPriyadharshini,                        
Dr. S. Mohanapriya for the moral support in pursuing my work. 
My heartfelt appreciation and love to my beloved juniors, Dr. Jisha G,          
Dr. K. Gayathri,  Dr. Rachel Sarah Vinodhini, Dr. J. Porkodi Sudha,                 
Dr. S. Renuga Devi, Dr. J. Swathi Raman for their unyielding support, love, care 
and constant motivation during the period of my study. 
 A special thanks to all my other co-post graduates for their constant care 
and support. 
My genuine and deep hearted thanks to my parents Mr.M.Ulaganathan,  
Mrs.U.Kalavathi, my sister Dr.M.U.Kaarthiha, my husband Dr. L. Balamurugan 
and to my beloved daughter Baby Thrishika Sri for their care, love, support and 
prayers to overcome all my hardships and relieving me from responsibilities and 
giving way to make up with my course and made me able to reach to this height. 
 
 
 CONTENTS 
 
S. No.   CONTENTS 
 
PAGE 
NO.  
1 INTRODUCTION  1-2 
2 AIM AND OBJECTIVES 3 
3 REVIEW OF LITERATURE 4-21 
4 MATERIAL AND METHODOLOGY 22-32 
5 RESULTS 33-49 
6 DISCUSSION 50-56 
7 SUMMARY  57-59 
8 CONCLUSION 60 
  
LIST OF TABLES 
S. No. TABLE TITLE 
PAGE 
NO. 
01 
Percentage of Annexin A1 positive cells and grading in well 
differentiated OSCC cases 
34 
02 
Percentage of Annexin A1 positive cells and grading in 
moderately differentiated OSCC cases 
35 
03 
Comparison of Annexin A1 grading in well differentiated and 
moderately differentiated OSCC cases (Chi-square test) 
36 
04 
Percentage of Ki-67 positive cells and grading in well 
differentiated OSCC cases 
37 
05 
Percentage of Ki-67 positive cells and grading in moderately 
differentiated OSCC cases 
38 
06 
Comparison of Ki-67 grading in well differentiated and 
moderately differentiated OSCC cases (Chi-square test) 
39 
07 
Comparison of percentage of Annexin A1 negative staining in 
normal buccal mucosa and negative margins of non-recurrent 
OSCC cases (Chi-square test) 
40 
08 
Comparison of percentage of AnnexinA1 negative staining in 
normal buccal mucosa and negative margins of recurrent OSCC 
cases (Chi-square test)  
41 
09 
Comparison of percentage of Annexin A1 negative staining in 
recurrent and non recurrent OSCC cases (Chi-square test) 
42 
10 
Comparison of percentage of Ki-67 positive expression in basal 
and suprabasal layers of normal buccal mucosa and negative 
margins of non-recurrent OSCC cases (Chi-square test) 
43 
11 
Comparison of percentage of Ki-67 positive expression in basal 
and suprabasal layers of normal buccal mucosa and negative 
margins of recurrent OSCC cases (Chi-square test) 
44 
12 
Comparison of percentage of Ki-67 positive expression in basal 
and suprabasal layers of negative margins of recurrent and non-
recurrent OSCC cases (Chi-square test) 
45 
 
LIST OF FIGURES 
S. No. FIGURE TITLE 
PAGE 
NO. 
01 
Annexin A1 is positioned between two negatively charged 
monolayers 
5 
02 Molecular structure of annexin A1 6 
03 
Principal cellular effects of Annexin A1 phosphorylation on 
the characterized residues 
8 
04 Molecular structure of Ki-67 13 
05 Hematoxylin and Eosin staining kit 29 
06 3-Aminopropyl triethoxysilane (APES) for coating IHC slides 30 
07 Secondary Antibody 30 
08 Anti human mouse polyclonal Annexin A1 antibody 31 
09 Anti human mouse monoclonal Ki-67 antibody 31 
10 
Research microscope with photomicrography attachment 
(LEICA DMD 108) 
32 
11 
Quantification of IHC staining by counting the number of 
cells by placing  the grid over the picture 
32 
12 
Photomicrograph showing expression of Annexin A1 in 
normal buccal mucosa (LEICA DMD 108, magnification 
10x) 
46 
13 
Photomicrograph showing expression of Annexin A1 in well 
differentiated OSCC (LEICA DMD 108, magnification 10x) 
46 
14 
Photomicrograph showing expression of Annexin A1 in 
moderately  differentiated OSCC (LEICA DMD 108, 
magnification 10x) 
47 
15 
Photomicrograph showing expression of Annexin A1 in the 
negative margin of non-recurrent OSCC (LEICA DMD 108, 
magnification 10x) 
47 
16 
Photomicrograph showing expression of Ki-67 in normal 
buccal mucosa (LEICA DMD 108, magnification 10x) 
48 
17 
Photomicrograph showing expression of Ki-67 in well 
differentiated OSCC (LEICA DMD 108, magnification 10x) 
48 
18 
Photomicrograph showing expression of Ki-67 in moderately 
differentiated OSCC (LEICA DMD 108, magnification 10x) 
49 
19 
Photomicrograph showing expression of Ki-67 in the negative 
margin of non-recurrent OSCC (LEICA DMD 108, 
magnification 10x) 
49 
 
LIST OF BAR DIAGRAMS 
S. No. TITLE 
PAGE 
NO. 
01 
Comparison of Annexin A1 grading in well differentiated and 
moderately differentiated OSCC cases  
36 
02 
Comparison of Ki-67 grading in well differentiated and 
moderately differentiated OSCC cases 
39 
03 
Comparison of percentage of Annexin A1 negative staining in 
normal buccal mucosa and negative margins of non-recurrent 
OSCC cases  
40 
04 
Comparision of percentage of AnnexinA1 negative staining in 
normal buccal mucosa and negative margins recurrent OSCC 
cases  
41 
05 
Comparison of percentage of Annexin A1 negative staining in 
recurrent and non recurrent OSCC cases 
42 
06 
Comparison of percentage of Ki-67 positive expression in basal 
and suprabasal layers of normal buccal mucosa and negative 
margins of non-recurrent OSCC cases     
43. 
07 
Comparision of percentage of Ki-67 positive expression in basal 
and suprabasal layers of normal buccal mucosa and negative 
margins of recurrent OSCC cases  
44 
08 
Comparison of percentage of Ki-67 positive expression in basal 
and suprabasal layers of negative margins of recurrent and non-
recurrent OSCC cases  
45 
  
 
Abbreviations 
 
ABBREVIATIONS 
List of Abbreviations Used 
OSCC Oral squamous cell carcinoma 
LR Local Recurrence 
HNM Histologically normal margins 
MAPK Mitogen-Activated Protein Kinases 
ERK Extracellular Signal-Regulated Kinases pathway 
EGF Epidermal growth factor (EGF) 
SH2 Src- homology 2 
Grb-2 Growth Factor Receptor-Bound 2 
APES 3-Amino Propyl triethoxy silane 
EDTA Ethylenediamine Tetraacetic Acid 
DPX Distrene dibutylpthalate xylene 
l Litre 
GR Guarnted reagent 
gms Grams 
PBS Phosphate buffered saline 
HRP Horseradish peroxidase enzyme 
 
                                                                                                                     
                                                                                                                     Introduction     
 
1 
 
INTRODUCTION 
Oral squamous cell carcinoma (OSCC), one of the most frequent malignant 
tumours worldwide, has major predominance in South-East Asia, in particularly India, 
accounting for 19% of the total cancer cases in men and 7% of that in women. Early 
diagnosis is the only saviour from this deadly disease and many measures are being 
explored worldwide to predict the occurrence and recurrence of the lesion.1  
“Local recurrence in OSCC is defined as tumor regrowth <2 cm away from 
the primary tumor and occurring within three years after providing treatment”.2 Local 
recurrence of oral squamous cell carcinoma occurs even in histologically negative 
surgical margins up to 10-30%3 and thus histological measures alone to predict the 
recurrence remains insufficient. Therefore, it is important to identify factors that are 
correlated with local recurrence in cases with clear margins.4 
Immunohistochemical (IHC) analysis is in the advancing front for diagnosis of 
changes at molecular level, and various IHC markers are utilized to predict the 
recurrence and facilitate treatment planning in oral squamous cell carcinoma patients.4 
Annexin A1 is one of the recent polyclonal antibody. Its expression has been 
studied in breast, lung, oesophageal, prostrate carcinomas and acts as a prognostic 
marker in OSCC cases.5 Other IHC marker is Ki-67, which is a well known cell 
proliferation marker and its nuclear expression is potentially useful for predicting 
recurrence in surgically treated stage 1 OSCC cases of tongue.6 
Annexin A1 
Annexin A1, the first characterized member of annexin superfamily, originally 
known as macrocortin, renocortin, lipomodulin, has been initially named as 
lipocortin-1 and, subsequently as Annexin A1.7 This 37 Kilo Dalton (KDa) protein is 
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found to have calcium and phospholipids binding properties and is actively involved 
in the inhibition of eicosanoid synthesis and Phospholipase A2 (PLA2), induced by 
glucocorticoids. The gene encoding this protein is located on chromosome 19q24.7 
In head and neck carcinomas, the expression of Annexin A1has been 
associated with advanced stage of the disease, metastasis, and differentiation status 
and could be an effective differentiation marker for the detection of epithelial 
dysplasia and histopathological grading of head and neck squamous cell carcinomas.7 
The role of Annexin A1 is complicated by the fact that, Annexin A1 is 
downregulated in some carcinomas, including gastric, breast, prostate, cervical and 
thyroid and OSCC, but up regulated in other types of cancer, such as pancreatic 
cancer.8 
Ki-67 
Ki-67 is a large non-histone protein of approximately 395 kDa, which has 
been used as a marker of proliferative activity during the G1, S, G2, and M phases of 
the cell cycle.  
Expression of Ki-67 in mean of proliferative activity of tumor cells is one of 
the indicators for tumor invasion potential and invasive activity of cancers related to 
degree of malignant neoplastic cells. Its expression is found to be increased in 
Dysplasia and SCC as compared to normal mucosa.9 
Thus the present study is aimed to predict the LR in OSCC cases by utilizing 
the IHC markers Annexin A1 and Ki-67. 
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AIM AND OBJECTIVES 
Aim  
To evaluate the expression of the IHC markers Annexin A1 and Ki-67 in 
histologically negative margins of surgically treated OSCC cases with and without 
local recurrences. 
Objectives 
1. To prepare the tissue blocks of normal buccal mucosa, surgically treated 
OSCC cases and their negative margins with and without local recurrences. 
2. To study the expression of the IHC markers Annexin A1 and Ki 67 in the 
three study groups. 
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REVIEW OF LITERATURE 
Annexin A1 
About 30 years ago, a 37 KDa protein was identified as a steroid induced 
inhibitor of phospholipase activity with potential anti-inflammatory action. The 
protein was named lipocortin-1, lipomodulin, macrocortin or renocortin. Currently it 
is mostly known as Annexin A1.10 Since then many researches and studies were done 
to prove its usefulness in cancer diagnosis and therapy. 
Structure of Annexin A1 
The name annexin is derived from the Greek word “annex” meaning 
“bring/hold together” and was chosen to describe the principal property of all or at 
least nearly all annexins, i.e., the binding to and possibly holding together of certain 
biological structures, in particular membranes.11 
Annexin A1 is a part of family of receptor tyrosine kinases (RTK) that 
includes Mer and Sky and expressed ubiquitously. The ligand of Annexin A1, Gas6 
protein, is so named by virtue of the initial finding that the gene (growth arrest-
specific gene 6) that encodes the protein is highly expressed in growth arrested cells.12 
This 37 kDa protein consists in a homologous core region of 310 amino acid 
residues, representing almost 90% of the structure, attached to a unique N-terminal 
region. In addition to mediating membrane binding, Ca2+ ions can also induce a 
conformational change that leads to the exposure of the bioactive N-terminal 
domain.13 
Annexins are structurally divided into a conserved core domain, which has the 
shape of a slightly curved disc, and a divergent N-terminal that is unique for a given 
member of the family. The core domain comprises four (in annexin A6 eight) 
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homologous repeats (labeled I–IV) of about 75 amino acid residues that fold into five 
alpha-helices (A–E) and form an anti-parallel bundle. High-resolution crystal 
structures have identified the calcium binding sites to be located on the convex face of 
the protein. The bound calcium ions serve as a hypothetical “bridge” between the 
protein and membrane by simultaneously coordinating ligands from acidic side chains 
of the protein and from phosphoryl moieties of the lipids.2 The N-terminal is variable 
in sequence and length for given members of the family, and is thought to regulate the 
specific physiological functions of each annexin A1.14 
 
 
 
 
 
 
 
 
 
 
 
(Figure-1): Annexin A1 is positioned between two negatively charged 
monolayers. Annexin A1 is color coded as red (repeat I), green (repeat II), blue 
(repeat III), yellow (repeat IV), and black (the N-terminal). The location of K26 
and K29 within the protein is indicated with an arrow. Calcium ions are shown 
as light-blue spheres. A 90 degree rotation provides an axial view of the 
protein.14 
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The structures of annexin A1 both in the presence and absence of calcium 
have been solved using X-ray crystallography techniques.14 The crystal structures of 
full-length annexin A1 in the absence and presence of calcium suggest a calcium 
dependent relocation of the N-terminal tail. In the apo-form, the N-terminal 26 amino 
acids fold into two a-helices with a tilt at Glu-17 and insert into the third repeat of the 
C-terminal domain. Residues 2–12 adopt an amphipathic conformation. The 
amphipathic character of the N-terminal helix suggests a direct interaction of the N-
terminal domain with membrane, possibly by annealing to the lipid surface. In the 
crystal structure of the calcium-bound form, the N-terminal domain was not found in 
its previous position, i.e., expelled from the third domain. Although the electron 
density of residues 1–40 could not be resolved, presumably because of the high 
flexibility of this region, NMR and CD study reported a helical conformation of 
human annexin A1 in membrane-mimetic environments.15 
 
 
(Figure-2): Molecular structure of annexin A1. Ribbon presentation showing the 
three-dimensional fold of the Ca backbone of annexin A1 in the presence (left) or 
absence (right) of Ca2+ ions.15 
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Annexin A1 in Normal Cells and Tissues 
The sub cellular phospho-Annexin A1 localization 
Hu Jen N et al., 2008 found Annexin A1 in rat liver mitochondria and proved 
that the protein was phosphorylated on tyrosine residues. Annexin A1 implication in 
growth regulation, differentiation and apoptosis has been reported and further studies 
were performed. 15 
Studies in human embryonic kidney HEK293 cells focused on Annexin A1 
cellular localization during PMA-induced mitogenic signal showed cleavage of 
Annexin A1 which then migrated into the nucleus. The PMA-induced nuclear 
translocation of Annexin A1 was inhibited by the PKC delta-specific inhibitor, 
rottlerin, indicating that PKC delta plays a role in nuclear localization of cleaved 
Annexin A1. Evenmore intriguing is that dexamethasone induces changes in 
phosphorylation and subcellular localization of Annexin A1, in A549 human 
adenocarcinoma cells. The Annexin A1 tyrosine phosphorylated co-localized with 
EGF-R, and its amount was increased upon dexamethasone exposition. This effect 
was reached in few minutes after dexamethasone stimulation and was surprisingly 
completely reverted by RU486, a known glucocorticoid receptor inhibitor.15 
It has been suggested that the phosphorylated Annexin A1 migrates to the cell 
membrane in order to interact with EGF-R. This result paved the way to the following 
studies about the Annexin A1 membrane localization. Nevertheless it was confirmed 
that Annexin A1 directly binds EGF-R during its internalization, but the binding is not 
dependent on the phosphorylation of the Annexin A1 N-terminus. In accord with 
these results, the binding between EGF-R and Annexin A1 seems to be mediated 
through the Ca2+ binding core domain. 10 
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(Figure-3): Principal cellular effects of Annexin A1 phosphorylation on the 
characterized residues10 
Annexin A1 in Breast Cancer 
Annexin A1 has been shown to be unregulated in breast, pancreatic, hepatic 
carcinomas but markedly downregulated in esophageal, prostate and gastric 
carcinomas.16 Clinically, breast cancer develops through sequential stages from 
normal ductal epithelium to hyperplasia, ductal carcinoma in situ (DCIS), invasive 
cancer, and metastatic carcinoma. Normally, Annexin A1 is distinctively expressed in 
the mammary gland during embryonic development, and hence the association 
between Annexin A1 and breast cancer development can be postulated. Decreased 
expression of Annexin A1 has been consistently reported at both the RNA and protein 
levels in breast cancer; however, the role of Annexin A1 expression in tumor 
initiation or progression has remained unclear.17 
Shen et al., 2010 in their study, have shown that Annxein A1 is increased in 
basal like or ER negative tumors and lower in luminal breast cancer, and decreased 
expression of Annexin A1 is correlated with breast cancer progression.16 
Yom et al., 2011 demonstrated in their study that Annexin A1 positive is 
related to poor breast cancer related survival and relapse free survival.17   
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In a Study by Leite SM., 2015 has shown that Annexin A1 is expressed in 
normal and benign breast lesions and lost during disease progression. Annexin A1 
expression is negatively correlated with survival.18  
Annexin A1 in Pancreatic Carcinoma 
According to Xiao-Feng Bai et al., 2004 over expression of Annexin A1 is a 
frequent event in pancreatic cancer, which may be one of the factors that link with the 
malignant transformation, lower differentiation and poor prognosis of pancreatic 
cancer. Detection of Annexin A1 expression may be assistant to clinical diagnosis and 
can assess the prognosis of pancreatic cancer.19 
In a study by Bedvedere R et al., 2016 Immunohistochemistry demonstrated 
that Annexin A1 was mainly expressed at the cell surface of pancreatic cancer cells. 
Interestingly, Annexin A1 overexpression in cancer cells was significantly associated 
with rapid recurrence after chemotherapy in postoperative patients. These results 
indicate that Annexin A1 overexpression may induce chemotherapy resistance in 
pancreatic cancer resulting in rapid recurrence.20 
Annexin A1 in Oesophageal Carcinoma 
In a study by Han et al., 2014 expression of Annexin A1 was dysregulated in 
oesophageal carcinoma.  Low expression of nuclear Annexin A1 had a better 
prognosis than those with high expression of nuclear Annexin A1, especially for those 
with histologic grade 1 and 2. They concluded that, nuclear Annexin A1 may be 
potentially used as a prognostic biomarker for oesophageal carcinoma.21 
According to Wang LK et al., 2006 high Annexin A1 expression was present 
in tumors associated with higher pathologic T stage and distant metastasis. High 
Annexin A1 expression correlated with increased recurrence rate and decreased 
overall survival rate.22 
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 Huang et al, in their study, postulated that, positive Annexin A1 expression is 
frequent in oesophageal squamous cell carcinoma. The expression of Annexin A1 was 
not associated with chemoradiation therapy sensitivity. However, it maybe serves as a 
novel prognostic biomarker for oesophageal squamous cell carcinoma (Huang H., 
2004).23 
Annexin A1 in Oral Premalignant Lesions 
According to Hitomi Nomura et al., 2009 tumor specimens of primary OSCCs 
and oral premalignant lesions were analysed for Annexin A1 subcellular localization 
and protein expression level by immunohistochemistry. Down-regulation of Annexin 
A1 protein expression was identified on the plasma membrane of the epithelial cells 
in OSCCs.24 
In a study by Lin Cy et al., 2008 the expression of Annexin A1 was compared 
in both oral epithelial dysplasia and OSCC. In normal oral mucosa, Annexin A1 
staining was predominantly located on the cell membrane. In Oral epithelial dysplasia 
and OSCC specimens, membranous staining decreased, whereas nuclear staining 
increased.25 
Annexin A1 Expression in Oral Squamous Cell Carcinoma 
 Dong-Wang Zhu et al., 2013 in their study has concluded that, there was a 
significant correlation between Annexin A1 expression and pathologic differentiation 
grade in OSCC patients. The proportion of patients with low Annexin A1 expression 
was significantly higher amongst those with moderate/poorly differentiated tumor 
compared to those with well differentiated tumor. Furthermore, a low Annexin A1 
expression level was predictive of longer disease free survival and locoregional 
recurrence-free survival compared to high Annexin A1 expression. Patients with 
moderate/poorly differentiated tumor and low Annexin A1 expression benefited from 
 
Review of literature 
 
11 
 
TPF induction chemotherapy as measured by distant metastasis-free survival as well 
as overall survival.1 
 In a study by Lei-Zang et al., 2009 the lower Annexin A1 protein expressions 
correlated with poorer pathologic differentiation grades. These results suggest that 
decreased expression of Annexin A1 contributes to the cancerous progression of oral 
squamous cell carcinoma and Annexin A1 may be a potential biomarker for 
pathologic differentiation grade of oral squamous cell carcinoma.26 
According to Lee et al., 2012 the immunoreactivity of Annexin A1 was low in 
normal epithelium, and a progressively increased positive percentage was noted, from 
normal/hyperplasic epithelium to dysplasia to cancer tissue. Patients with high 
expression of Annexin A1 showed poor prognosis compared with those with low 
Annexin A1 expression patients. This study concluded that Annexin A1 signal 
promotes oral squamous cell carcinogenesis and progression and also it is a valuable 
marker for OSCC aggressiveness and clinical outcome.12 
 Chiao Ying Lin et al., 2008 in their study, immunohistochemically examined 
the expression of Annexin A1 and concluded that, in normal oral mucosa, Annexin 
A1 staining was predominantly located on the cell membrane. In oral epithelial 
dysplasia and OSCC specimens, membranous staining decreased, whereas nuclear 
staining increased. Positive nuclear staining indicates overall poor survival. The 
nuclear localization of Annexin A1 protein is a frequent event and could be used as a 
prognostic factor in oral squamous cell carcinoma.25 
KI-67 
The Ki-67 protein is a nuclear and nucleolar protein, which is tightly 
associated with somatic cell proliferation. Antibodies raised against the human Ki-67 
protein paved the way for the immunohistological assessment of cell proliferation, 
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particularly useful in numerous studies on the prognostic value of cell growth in 
clinical samples of human neoplasms (Endl E., 2000).27 
Cell proliferation is a biological process of vital importance and this control is 
lost in cancer. Therefore, the knowledge of cellular proteins that control cell 
proliferation is essential for understanding tumor biology. Ki-67 antigen is a specific 
marker of proliferating cells. Studies have shown a highly significant correlation 
between Ki-67 staining and the malignancy degree, and a marked variation within 
different tumor grades, indicating that Ki-67 staining is useful in tumor diagnosis and 
prognosis. Various investigators have studied the Ki-67 expression at the invasive 
tumor front and also at the center of the tumor sections and have proved that Ki-67 
labelling index at the invasive front is superior for prognostic purposes .28 
Structure of Ki-67 
 Ki-67 is a nuclear DNA-binding protein with two human isoforms that have 
predicted molecular weights of 320kDa and 359kDa. All homologues contain an N-
terminal Forkhead-associated (FHA) domain, which can bind both to DNA and to 
phosphorylated epitopes. The most characteristic feature of Ki-67 is the presence of 
multiple tandem repeats (14 in mice, 16 in human) containing a conserved motif of 
unknown function, the 'Ki-67 domain'. Two other conserved motifs include a Protein 
Phosphatase 1 (PP1)-binding motif and a 31 amino acid conserved domain (CD) of 
unknown function, 100% identical between human and mouse, that includes a 22 
amino acid motif conserved in all homologues. Ki-67 homologues also have a weakly 
conserved leucine/arginine rich C-terminus which can bind to DNA and, when 
overexpressed, promotes chromatin compaction.29 
  Ki-67 protein levels and localisation vary through the cell cycle. Its maximum 
expression is found in G2 phase or during mitosis. In interphase, Ki-67 forms fibre-
  
like structures in fibrillarin
colocalises with satellite DNA and is found in protein complexes that bind to sate
DNA. It remains associated with nucleolar organiser regions of acrocentric 
chromosomes throughout interphase. Ki
dependent kinase CDK1 and is hyperphosphorylated in mitosis. This may regulate its 
expression and / or localisation. In HeLa cells, Ki
interphase, whereas this binding is weakened in mitosis when it associates with 
condensed chromosomes before relocating to the chromosome periphery
(Figure-4): Molecular structure of Ki
dimensional fold of the Ca backbone of Ki
 
Functions of Ki-67 
Ki67 is frequently used as an indicator of cell proliferation. A number 
diagnostic applications for 
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using antibodies reactive against various proliferating cellular antigens. The Ki-
67/MIB-1 monoclonal antibody is commonly used, and is reactive against the nuclear 
antigen Ki-67 that is expressed during cell cycle phases G1, S, G2 and M, but is not 
found during G0. The percentage of immunoreactive tumor cell nuclei is expressed as 
a labeling index (LI). Studies thus far have all shown a positive correlation between 
Ki-67/MIB-1 LI and tumor grade in human malignancy. Due to the limitations of 
routine histological examination of tumor tissue in predicting tumor behavior, 
Ki67/MIB-1 immunostaining has been introduced for its potential to improve the 
information provided by the grading system. Its presence in a variety of tumors 
indicates that it may be possible to use Ki-67 in routine grading of cancer. Judicious 
use of this proliferation marker in combination with established histopathological 
features of malignancy may serve as a more reliable indicator of the likelihood of 
tumor recurrence.30 
The data on Ki-67 as a diagnostic marker is scarce and based on varying 
laboratory and statistical methods. Cancer has a complex pathogenesis and reliable 
early diagnosis is difficult. Symptoms usually do not appear until the disease has 
progressed to an advanced stage. Therefore, further research into diagnostic and 
prognostic markers may aid early diagnosis. Notably, the expression of Ki-67 reflects 
the tumor proliferation rate and correlates with initiation, progression, metastasis and 
prognosis of a number of types of tumors. Certain regulators of these processes, such 
as Smac, minichromosome maintenance 7, p53, Bcl-2, proliferating cell nuclear 
antigen (PCNA) and CD105 have been investigated.30 
In a number of studies, Ki-67 appeared to be closely correlated with pancreatic 
tumor severity as well as with expression of Smac and thus may be useful as a 
diagnostic and prognostic marker or, in conjunction with Smac, as an indicator of 
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treatment efficacy. In a further study, Chen et al reported that utilizing Ki-67 LI and 
vascular endothelial growth factor scoring is useful to effectively and accurately 
predict outcomes and optimize personal therapy in judging the outcomes of non-
muscle invasive bladder cancer. This novel molecular grading system could enhance 
the efficiency of the conventional system. MIB-1 is a monoclonal antibody that 
recognizes a fixation resistant epitope of the Ki-67 antigen and it is used to estimate 
the proliferative fraction of neoplasia. Using MIB-1, it was observed that Ki-67 LI 
was high in Grade I and Grade II as compared with the Grade III carcinoma.30 
Ki-67 in Breast Cancer 
Eramiah et al., 2012 postulated that, high Ki-67 was associated with advanced 
stages, poor differentiation of tumors, positive lymph nodes and distant metastasis. In 
the overall population, patients with high Ki-67 had shorter survival time and 
predicted recurrence than patients with low Ki-67. The Ki-67 in borderline 
significance proved to be independent predictor of disease-free survival.31 
Mohamed et al., 2011 in their study concluded that, Ki-67 immunoreactivity 
was significantly associated with poor prognostic clinicopathological parameters 
including old age, high tumor grade and lymph node metastasis. The Ki-67 positive 
index was significantly associated with breast cancer molecular subtypes that were 
Her2/neu positive (luminal B and HER-2) subtypes compared with the Her2/neu 
negative (luminal A) subtype.32 
 In this study by Velappan et al., 2017 it was confirmed that Ki-67 is a 
prognostic factor in breast cancer patients. A higher Ki-67 index correlated 
significantly with young age, larger tumors, and positive lymphnodes. The 
proliferative activity as determined by Ki-67 index may reflect the aggressive 
 
Review of literature 
 
16 
 
behavior of breast cancer. It is therefore important to incorporate the Ki-67 index in 
the routine clinical settings.33 
Ki-67 in Pancreatic Carcinoma 
 According to Hamilton AN et al., 2012 increasing tumor size larger than 9cm 
and increasing Ki-67 staining both correlate with increased risk of disease recurrence 
and decreased overall survival.34 
 In a study by Mc Call et al., 2013 it was concluded that, mitotic rate and Ki-
67 based grades of pancreatic carcinomas are often discordant, and when Ki-67 grade 
is greater than the mitotic grade, clinical outcome and histopathologic features are 
significantly worse than concordant grade 1 tumors. Patients with discordant mitotic 
grade1/Ki-67 grade 2 tumors have shorter overall survival and larger tumors with 
more metastases and more aggressive histologic features.35 
 Linder S et al., 1997 in their study, postulated that, Ki-67 index greater than 
2% at either the primary site or the metastatic site was found to be the only significant 
predictor of progression free survival of patients with pancreatic carcinomas.36 
Ki-67 in Oesophageal Carcinoma 
 According to Hisami Sasagava et al., 2012 the recurrence of tumor is higher in 
patients with more than or equal to 35% labelling index than with labelling index of 
less than 35%. By correlating this with lymphnode metastasis, it can be used as a 
prognostic factor for esophageal carcinoma.37 
 In a study by Bellini et al., 2010 the Ki-67 labelling index has been identified 
as a parameter reflecting tumour proliferation. Oesophageal carcinoma patients with a 
high Ki-67 labelling index have lower postoperative survival rates; thus, a high Ki-67 
labelling index is one of the prognostic factors of oesophageal carcinoma.38 
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 Hong TK et al., 1995 in their study concluded that, malignant esophageal 
tumors have high Ki-67 positive index.39 
 In a study by Amrani HJ et al., 2014 high scores of Ki-67 are found in 
advanced TNM stages. Consequently, Ki-67 may be useful in identifying a group of 
patients with aggressive tumors and also the rate of K-i67 before neoadjuvant 
chemotherapy is a strong predictor of efficacy of the therapy. After neoadjuvant 
chemotherapy, lower values of Ki-67 indicate a better prognosis.40    
Ki-67 in Oral Premalignant Lesions 
According to Humayun S et al., 2011 Ki-67 staining intensity increases as 
normal oral mucosa becomes dysplastic and undergoes malignant transformation.41 
Birajdar et al., 2014 in their study, stated that, Ki-67 labeling Index was 
restricted to the basal and parabasal layers of the normal oral epithelium irrespective 
of age sex and site whereas it was seen in the basal, suprabasal and spinous layers in 
oral epithelial dysplasia. Ki-67 labelling index is increased in high risk cases than the 
low risk cases of oral epithelial dysplasia. Ki-67 positive cells in oral squamous cell 
carcinoma were located in the periphery of the tumor nests than the center, where 
frequent mitoses were observed.42 
 In a study by, Maheshwari V et al., 2013 the expression Ki-67 correlates well 
with the disease progression from dysplasia to carcinoma of the oral cavity. It is 
therefore a marker of malignant transformation and carcinogenesis in oral 
premalignant lesions and in future it may act as a prognostic tool for early detection of 
malignancy.43 
 Priya K et al., 2012 in their study concluded that, Ki-67 was found to increase 
significantly with an increase in the grade of dysplasia and predicts the severity of the 
lesion.44 
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 Patel et al., 2014 postulated that, there was a strong association was found in 
expression of Ki-67 in premalignant and malignant oral lesions in compared to normal 
mucosa. Increased expression of Ki-67 immunostain was significantly correlated with 
progression of oral epithelium from normal to neoplasia and increased expression of 
this antigen suggest that they may be useful indicator of malignant transformation in 
dysplastic lesions.45 
 According to Angiero et al., 2008 the expression of Ki-67 in the dysplastic 
epithelium may represent as a significant marker to recognize evolution of 
precancerous disease in the oral cavity and to improve identification of the degree of 
dysplasia.46 
 Dwivedi N et al., 2013 in their study, demonstrated the use of proliferative 
marker Ki-67 in assessing the severity of epithelial dysplasia. Suprabasal expression 
of Ki-67 provides objective criteria for determining the severity of epithelial dysplasia 
and histological grading of oral squamous cell carcinoma.47 
 Raju B et al., 2005 concluded that, in oral mucosal lesions, the expression of 
Ki-67 has been reported to increase according to the proliferative activity and degree 
of epithelial dysplasia, suggesting that it is a marker of the presence and severity of 
epithelial dysplasia.48 
According to Roy S et al., 2009 staining with Ki-67 was found to be quite 
high, with a stronger intensity especially in the oral dysplasias. It is of great interest to 
note that Ki-67 over expression have been suggested to be reliable indicators for oral 
carcinoma development.49 
Ki-67 in Oral Squamous Cell Carcinoma 
Hoffman et al., 2012 in their study stated that, the prognostic relevance of Ki-
67 expression in OSCC is still controversial. As proliferating cells are more 
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susceptible to ionizing radiation, the authors investigated if a high proliferation rate 
reflected by Ki-67 expression, predicts radiosensitivity in OSCC patients. This study 
indicates that tumours with high proliferative activity are more susceptible to 
radiation therapy. Ki-67 might be used as a marker to predict the response to radiation 
therapy in patients with OSCC.50 
Warnakulasuriya et al., 2003 in their study have reported expression of Ki-67 
at the tumour infiltrating front of oral carcinomas with a strong positive correlation to 
the histological grading of the carcinoma.51 
In a study by Sassi L M et al., 2011 analysing the Ki-67 nuclear expression 
may constitute an auxiliary method for prognosis of OSCC patients. 
Immunoexpression of the Ki-67 may be of great help for evaluate the probability of 
second primary tumor development because of its statistically relevant indication of 
cell proliferation.52 
Premalatha et al., 2010 concluded that, a statistically significant difference 
was obtained only between Ki-67 labelling index of well and poorly differentiated 
OSCC cases. Ki-67 labelling index of moderately differentiated OSCC cases did not 
have statistically significant difference with either well or poorly differentiated cases.6  
According to Xie et al., 2016 Ki-67 expression is low during G1- and early S-
phase, but progressively increases to reach maximum during mitosis. This indicated 
that Ki-67 might be applied as a marker for different conditions of cell growth. Cell 
proliferation is closely related to tumor recurrence. Thus, Ki-67 might be regarded as 
a potential molecular indicator in the prognosis of a tumor.53 
Moles et al., 2010 stated that, Ki-67 expression was significantly higher in 
well-differentiated versus poorly-differentiated carcinomas. The survival time of these 
patients was affected by the clinical presentation, T, N, stage, and surgical treatment. 
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Ki-67 expression had no impact on survival. An association was found between the 
parabasal expression of Ki-67 in adjacent non-tumor epithelium and Ki-67 expression 
in the tumor.54 
Tumuluri V et al., 2002 have studied the relationship of Ki-67 labelling index 
at the invasive front of the OSCC cases with the histological grading and have 
concluded that expression of Ki- 67 at the deep invasive tumor front of OSCC is 
associated with histologic grade of malignancy.55  
Cortegosa A et al., 2016 have compared the Ki-67 labelling index at the 
invasive front and at the center of the tumor and have proved that Ki-67 labelling 
index at the invasive front is superior for prognostic purposes when compared to Ki-
67 labelling index obtained from the center of the tumor.56 
Bankfalvi A et al., 2000 in his study have found that Ki-67 is a specific marker 
for cell proliferation and is abundantly expressed in the S-phase of cell cycle and 
disappears immediately after mitosis due to its shorter half life. Ki-67 has increased 
expression in the centre and advancing fronts of OSCC cases.57 
Bryne M et al., 1998 advocated that the invasive tumor front is the most 
important area for prognostic determination of oral cancer. It consists of many 
molecular and morphological characteristics that reflect tumor progression better than 
other parts of the tumor. Several molecular events of importance for tumor spread 
such as gains and losses of adhesion molecules, secretion of proteolytic enzymes, 
increased cell proliferation and initiation of angiogenesis occur at the invasive front. 
High Ki-67 labelling index in the invasive tumor front acts as a predictor for 
malignancy.58 
According to Kurokawa et al., 2005 the proliferation index, as assessed by 
expression of Ki-67, was highest in the malignant lesions and lowest in normal 
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mucosa. Its expression was correlated significantly with the histopathological stage of 
the tumour. 
59  
 Pereira et al., 2016 observed low Ki-67 expression in the tumour invasive 
front  and suggests that this may be due to the analysis of cell proliferation has only 
been performed in invasive front, so it can be inferred that proliferative activity in this 
region is low and could be influenced by other factors the tumor microenvironment.60 
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MATERIALS AND METHODS 
Sample Source 
Specimens for the study are selected from the archives of Department of Oral 
and Maxillofacial Pathology. 
Inclusion Criteria 
1) Specimens of normal buccal mucosa obtained from apparently healthy patients 
without any premalignant and malignant lesions, during minor oral surgical 
procedures, after obtaining informed consent from the patient.  
2) Specimens/tissue blocks of surgically treated OSCC cases histopathologically 
diagnosed as well, moderate and poorly differentiated and their negative 
margins. 
Exclusion Criteria 
1) Specimens of normal buccal mucosa from individuals with long standing 
tobacco related habits. 
2) Carcinomas of sites other than oral cavity proper like oropharynx, maxillary 
sinus etc. 
3) Tissues without adequate size. 
Sample Size 
The study group comprises of: 
Group I- 10 specimens of apparently normal buccal mucosa  
Group II- 20 specimens/tissue blocks from the Tumor Proper region of 
surgically treated OSCC cases (10 cases of well differentiated, 10 cases of 
moderately differentiated). 
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Group III- 20 specimens/tissue blocks of the negative margins of the above 
surgically treated OSCC patients. (Of which 15 cases are without local 
recurrence and 5 cases are with local recurrence) 
All the above 3 groups are subjected to immunohistochemical staining to 
evaluate the expression of Annexin A1and Ki 67 antibodies.   
Study Method 
Once the cases have been chosen, their paraffin embedded tissue blocks of the 
3 groups are sectioned to prepare three serial sections of 3 to 5 microns thickness. One 
section is stained with haematoxylin and eosin, and the other two are 
immunohistochemically stained with Annexin A1 and Ki-67 markers.  
The haematoxylin and eosin slides of OSCC cases are evaluated and graded 
according to Broder’s grading system (as well, moderately differentiated and poorly).  
Immunohistochemistry for Annexin A1 and Ki 67 expression is carried out using 
standard immunoperoxidase technique. The IHC stained sections are viewed using 
bright field light microscope (LEICA DMD 108) (Figure-10) and their 
photomicrography is captured as 10 x magnification. The analysis of Annexin A1 and 
Ki-67 expression is carried out on the basis of the percentage of cells showing 
staining in the different layers of the oral mucosa.  
Equipments and materials used in the study 
 Rotary microtome – (LEICA, Germany)  
 Slide warmer for dewaxing 
 Water bath at 600 C 
 Pressure cooker 
 Humidifying chamber 
 Research microscope with photomicrography attachment (Figure-10) 
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 3-Amino Propyl triethoxy silane (APES) precoated slides (Figure-6)  
 Ependorff tubes 
 Micropipettes  
 Plastic disposable pipette tips 
 Cover slips 
 Mayer’s Hematoxylin (Sigma-aldrich, U.S.A ) 
 Harris Hematoxylin (Sigma-aldrich, U.S.A ) 
 Eosin (Sigma-aldrich, U.S.A ) 
 Tris Ethylenediamine Tetraacetic Acid (EDTA) buffer (antigen retrieval) – 
pH: 9 
 Phosphate wash buffer (pH: 7.4) 
  3% Hydrogen Peroxidase block 
 Mouse polyclonal Annexin A1 antibody (Figure-8) 
 Mouse monoclonal Ki 67 antibody (Figure-9) 
 Secondary antibody (Figure-7) 
 3-diaminobenzidene tetra hydrochloride chromogen (DAB 3)   
 Distilled water 
 Iso-propyl alcohol 
 Xylene   
 Distrene dibutylpthalate xylene ( DPX) mountant  
Preparation of Buffers 
Tris EDTA buffer pH 9 (antigen retrieval) 
Preparation  
 Distilled water- 1 litre (l) 
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 Tris buffer Guarnted reagent (GR)- 6.05 grams (gms) 
 Disodium EDTA- 0.75gms 
Phosphate Buffer Saline preparation. pH 7.4 
 Preparation 
 Potassium dihydrogen phosphate – 3.6 gms  
 Sodium chloride -25.5 gms  
 Di-sodium hydrogen orthophosphate – 26.25 gms 
 Distilled water – 3 l 
Dilution of primary antibody   
 Mouse polyclonal Annexin A1 antibody and Mouse monoclonal Ki-67 in a 
dilution of 1:50 in phosphate buffered saline (PBS). 
Preparation of substrate chromogen solution 
 1 ml of buffered substrate solution is transferred into the calibrated ependorff 
tube. To this one drop (approximately 50l) of DAB chromogen is added.  
Methodology 
Processing Procedure 
Hematoxylin and Eosin Staining Procedure (Fig-5) 
 Slides are kept on hot plate for dewaxing. Dewaxing is completed in xylene 
and hydrated through graded alcohols to water.  
 Sections are stained with alum Hematoxylin for 5 minutes followed by 
differentiation in 1% acid alcohol for 2-3 seconds. Sections are washed well in 
running tap water and kept in the same for bluing for 10 minutes. 
 Slides are dipped in eosin twice and washed in running tap water for 1 minute. 
Slides are dehydrated through graded alcohols, dried and mounted with DPX. 
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Immunohistochemical Staining Procedure 
1. Sectioning: Two to three serial sections of 3-5µm thickness are made on 
APES coated slides. 
2. Deparaffinization: The sections are deparaffinised by heating on the slide 
warmer at 60°C for 1 hour. 
3. Dehydration: The sections are dewaxed in 2 changes of xylene, each for 15 
minutes and rehydrated in descending grades of alcohol (100%, 90%, 70%, 
and 50%) and then changed to water each for 5 minutes. 
4. Antigen Retrieval: The slides are placed in a coplin jar, with Tris EDTA 
buffer (pH 9) solution. Antigen retrieval is performed under steam pressure 
using pressure cooker for 20 minutes. 
5.  IHC staining procedure: All the reagents stored in the refrigerator are 
brought to room temperature prior to immunostaining. All the incubations are 
performed at room temperature using a humidifying chamber. At no time the 
tissue sections are allowed to dry during the staining procedure. 
Step 1: Blocking of peroxidase activity: After tapping off the excess 
buffer from the slide, the sections are covered with 3% hydrogen peroxide for 
10 minutes to block endogenous peroxidase activity, and then the slides are 
washed gently with PBS and kept in the PBS buffer bath for 5 minutes 
followed by treatment with protein block for 10 minutes. 
 Step 2: Primary antibody application: The sections are covered 
completely with optimally diluted anti human mouse polyclonal Annexin A1 
antibody and anti human mouse monoclonal Ki 67 in a dilution of 1:50 in PBS 
for half an hour.  Then the slides are washed gently with PBS and kept in the 
PBS buffer bath for 5 minutes. 
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 Step 3: Secondary antibody application: The slides are covered 
completely with polyexcel target binder and incubated for 10 minutes, then the 
slides are washed and treated with polyexcel Horseradish peroxidase enzyme 
(HRP) (PathnSitu) for 10 minutes. 
 Step 4: Substrate chromogen application: The slides are again washed 
with PBS and immunostaining is carried out by incubating in DAB substrate 
solution for 5 minutes following which it is washed in distilled water to 
remove excess chromogen. 
 Step 5: Counter stain: The slides are immersed in Mayer’s 
hematoxylin for 1 minute, and bluing is done in running tap water for 10 
minutes. 
 Step 6: Mounting: The sections are dehydrated in ascending grades of 
alcohol; air dried thoroughly and mounted using DPX. 
Interpretation of staining  
 The immunostained slides are observed for positivity under 4x/10x/40x 
magnifications and recorded with a high quality photomicrograph (LEICA 
DMD108).   
 In each case of OSCC, the tumor proper region and their histologically 
negative margins are analyzed. 
 Three proliferative areas from TP slides are chosen and their 
photomicrography is captured as 10x. Grids are placed over the picture and 
100 cells are counted from each selected area. Thus, totally 300 cells are 
evaluated for IHC expression in each slide. 
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 Presence of brown colored end product at the site of target antigen is 
considered as positive immunoreactivity. Absence of brown color end product 
is considered as negative staining. 
 The positive expression of the antibodies (Intracytoplasmic expression of 
Annexin A1  and intranuclear expression of Ki-67) in the tumor proper region 
of each case of OSCC is examined and graded as per as the score given 
below,76 
Score 0 = no staining or unspecific staining of tumor cells; (Negative) 
Score 1 = weak (intensity) and incomplete staining (quality) of more 
than 10% of tumor cells (quantity); (mild) 
Score 2 = moderate and complete staining of more than 10% of tumor 
cells; (moderate)   
Score 3 = strong and complete staining of more than 10% of tumor 
cells. (intense) 
The scoring in the tumor proper region of well differentiated and moderately 
differentiated OSCC cases for Annexin A1 and Ki-67 are compared.  
 After recording the expression of the markers in the tumor proper region, their 
negative margins are analyzed. Here, we noted the percentage of staining as 0-
25%, 25-50%, 50-75% and 75-100%. Percentage of negative expression of 
Annexin A1 and positive expression of Ki-67 are calculated and their final 
mean value is recorded and taken for statistical analysis.  
 Normal buccal mucosa is also examined similarly with both the IHC markers 
and their expression is noted as 0-25%, 25-50%, 50-75% and 75-100%. 
 The percentages of expression of both the markers in the margins of recurrent 
and non-recurrent OSCC cases
mucosa. 
 Also, the percentage
and non-recurrent OSCC cases is
Statistical Analysis 
 All the parameters are
Statistical Package for Social Science (SPSS) software version 17.
 The differences in 
the different grades of oral squamous
margins are statistically analyzed using the Chi square test. 
 The level of significance P<0.05
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(Figure-6): 3-Aminopropyl triethoxysilane (APES) 
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(Figure-8): Anti human mouse polyclonal Annexin A1 antibody 
 
 
 
(Figure-9): Anti human mouse monoclonal Ki-67 antibody 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
(Figure-10): Research microscope with photomicrography 
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RESULTS 
The study group comprises of 
Group I- 10 specimens of apparently normal buccal mucosa 
Group II- 20 specimens/tissue blocks from the tumor proper region of 
surgically treated OSCC cases (10 cases of well differentiated, 10 cases of 
moderately differentiated). 
Group III- 20 specimens/tissue blocks of the negative margins of the above 
surgically treated OSCC patients. (Of which 15 cases are without local 
recurrence and 5 cases are with local recurrence) 
All the above 3 groups are subjected to immunohistochemical staining to evaluate the 
expression of Annexin A1and Ki 67 antibodies.   
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Expression of Annexin A1 And Ki-67 in the Tumor Proper Region of Well and 
Moderately Differentiated Oscc Cases 
(Table-1): Percentage of Annexin A1 positive cells and grading in well 
differentiated OSCC cases 
S. No. 
Percentage of intracytoplasmic 
Annexin A1 positive cells 
Score Grade 
01 90.3% 03 Intensive 
02 83.0% 02 Moderate 
03 91.6% 03 Intensive 
04 91.6% 02 Moderate 
05 82.6% 03 Intensive 
06 87.3% 02 Intensive 
07 90.6% 02 Moderate 
08 87.0% 03 Intensive 
09 84.0% 03 Intensive 
10 86.0% 03 Moderate 
Out of 10 cases of well differentiated OSCC, 6 (60%) cases show intense 
expression and 4 (40%) case show moderate expression. None of the cases show mild 
expression. Grading is done based on intracytoplasmic expression. 
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(Table-2): Percentage of Annexin A1 positive cells and grading in moderately 
differentiated OSCC cases 
S. No. Percentage of intracytoplasmic 
Annexin A1 positive cells 
Score Grade 
01 71.6% 02 Moderate 
02 69.6% 02 Moderate 
03 70.6% 02 Moderate 
04 71.3% 02 Moderate 
05 62.6% 01 Mild 
06 75.0% 03 Intensive 
07 59.3% 02 Moderate 
08 53.0% 01 Mild 
09 71.6% 02 Moderate 
10 71.0% 02 Moderate 
Out of 10 cases of moderately differentiated OSCC, 2 (20%) cases show mild 
expression, 7 (70%) cases show moderate expression and 1 case (10%) show intense 
expression.  Grading is done based on intracytoplasmic expression. 
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(Table-4): Percentage of Ki-67 positive cells and grading in well differentiated 
OSCC cases                                                                                                                             
S.NO. 
Percentage of intranuclear 
Ki-67 positive cells 
Score Grade 
01 31.3% 03 Intensive 
02 35.3% 02 Moderate 
03 09.6% 02 Moderate 
04 32.0% 02 Moderate 
05 13.0% 02 Moderate 
06 15.3% 02 Moderate 
07 12.3% 02 Moderate 
08 13.6% 01 Mild 
09 11.0% 02 Moderate 
10 20.0% 03 Intensive 
 
Out of 10 cases of well differentiated OSCC 1 (10%) case show mild 
expression, 7 (70%) cases show moderate expression and 2 cases (20%) show intense 
expression. None of the cases show intracytoplasmic expression. Grading is based on 
intranuclear expression.  
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(Table-5): Percentage of Ki-67 positive cells and grading in moderately 
differentiated OSCC cases                                                                                                                             
S. No. 
Percentage of intranuclear Ki-
67 positive cells 
Score Grade 
01 57.3% 03 Intensive 
02 32.0% 03 Intensive 
03 15.3% 02 Moderate 
04 43.0% 02 Moderate 
05 53.3% 03 Intensive 
06 28.0% 02 Moderate 
07 39.0% 02 Moderate 
08 29.3% 03 Intensive 
09 33.0% 03 Intensive 
10 41.0% 03 Intensive 
 
Out of 10 cases of moderately differentiated OSCC 4 (40%) cases show 
moderate expression and 6 cases (20%) show intense expression. None of the cases 
show intracytoplasmic expression. Grading is based on intranuclear expression.  
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(Figure-12): Photomicrograph showing expression of Annexin A1 in normal 
buccal mucosa (LEICA DMD 108, magnification 10x) 
 
(Figure-13): Photomicrograph showing expression of Annexin A1 in well 
differentiated OSCC (LEICA DMD 108, magnification 10x) 
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(Figure-14): Photomicrograph showing expression of Annexin A1 in moderately 
differentiated OSCC (LEICA DMD 108, magnification 10x) 
 
 (Figure-15) Photomicrograph showing expression of Annexin A1 in the negative 
margin of non-recurrent OSCC (LEICA DMD 108, magnification 10x) 
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(Figure-16) Photomicrograph showing expression of Ki-67 in normal buccal 
mucosa (LEICA DMD 108, magnification 10x) 
 
(Figure-17): Photomicrograph showing expression of Ki-67 in well differentiated 
OSCC (LEICA DMD 108, magnification 10x) 
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(Figure-18): Photomicrograph showing expression of Ki-67 in moderately 
differentiated OSCC (LEICA DMD 108, magnification 10x) 
 
(Figure-19): Photomicrograph showing expression of Ki-67 in the negative 
margin of non-recurrent OSCC (LEICA DMD 108, magnification 10x) 
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DISCUSSION 
OSCC is an aggressive cancer frequently associated with poor prognosis. 
Five-year survival rates remained essentially unchanged over the past 20 years despite 
advancements in treatment.61 This is partly due to patients dying from metastatic 
disease despite being diagnosed at an early stage. Detection of occult metastases is 
difficult, which is why prognostic markers in primary diagnostic tumour specimens 
are highly desirable.62 
Despite an understanding of several clinicopathological factors such as lymph 
node metastasis and pattern of invasion at the tumor front that are known to correlate 
with poor survival, there is currently no method to definitively determine the 
prognosis of OSCC patients. The status of resection margins is one of these important 
factors because tumor cells or dysplastic epithelia that remain in the margins may lead 
to the local recurrence (LR) of OSCC and treatment failure. 63 
Traditionally, surgeons and pathologists have classified surgical margins as 
involved margins (margin ≤1 mm), close margins (margin 1–5 mm) or clear margins 
(margin >5 mm). Despite improvements over recent decades in surgical technology, 
chemotherapy, and radiation, the rate of LR remains as high as 25–45%. When the 
surgical margins are ‘clear’ (according to histological diagnosis), the LR rate remains 
10–30%.64 Therefore, histological diagnosis of the surgical margin alone is 
insufficient to predict the LR of head and neck SCC, particularly for ‘clear margins’ 
without epithelial dysplasia under traditional microscopic examinations. Therefore, it 
is important to identify factors those are correlated with relapse in cases with clear 
margins. Performing molecular analysis to access genetic changes related to the 
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carcinogenesis of OSCC may help clinicians to establish a prognosis and facilitate 
treatment planning in OSCC patients.65  
Reis et al., 2009 hypothesized that histologically normal margins (HNM) that 
share the same changes in marker expression as those observed in OSCC could be an 
early indicator of LR. However, the genetic marker changes that lead to OSCC remain 
unclear. Epidemiological studies suggest that the development and progression of 
tumors are caused by stepwise genetic alterations involving both the activation of 
proto-oncogenes and the inactivation of tumor suppressor genes.66 Previous studies 
using genetic markers and immunohistochemical methods have shown that the 
presence of altered cells in surgical margins is highly predictive of LR; these margins 
may share some but not all of the genetic alterations with their matched primary 
cancer.67 
Anti-proliferative activity of Annexin A1 and proliferative activity of the Ki-
67 nuclear antigen is linked to prognosis and treatment prediction with varying results 
in oral cancer, with few studies performed exclusively in OSCC cases. It is hereby 
investigated that whether Annexin A1 and Ki-67 expression can be of clinical use for 
prediction of locoregional recurrence exclusively in primary OSCC. 
The results of this study provide data on Annexin A1 and Ki-67 expression in 
the tumor proper region and histopathologically negative margins of well and 
moderately differentiated OSCC cases with and without LR.  The evaluation of 
expression of the IHC markers, Annexin A1 and Ki 67 can help us to predict the LR 
of OSCC cases. Thus by predicting the LR, surgeons can be intimated for wide local 
excision, thereby preventing treatment failures and benefiting the patients. 
On reviewing the literature, no other studies have been found to be performed 
with Annexin A1 antibody in negative margins of OSCC cases. In this present study, 
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we analyzed  the margins of 5 OSCC cases with recurrence, 15 OSCC cases without 
recurrence, 10 cases of normal buccal mucosa is used as a control. Basal and 
suprabasal layers of these 3 groups have been observed for negative staining and a 
comparison between these three groups are performed using Chi-square test. In 
normal buccal mucosa, strong positive Annexin A1 staining have been detected in 
differentiated and non-proliferating squamous cells, with negative staining in the 
proliferative layers of epithelia (basal and suprabasal) (Figure-12).  On analyzing the 
negative margins of non-recurrent OSCC cases, 11 cases show negative staining of 0-
25% and 4 cases show 25-50%. In case of negative margins of recurrent OSCC cases 
1 case shows 25-50%, 2 cases show 50-75% and 2 cases show 75-100% of negative 
staining respectively (Figure-15). 
A highly significant P-value of 0.002 is obtained on comparing the normal 
buccal mucosa with negative margins of non-recurrent OSCC cases. A comparison 
between normal buccal mucosa and negative margins of recurrent OSCC cases have 
been performed, which gives a less significant P-value of 0.012. Finally, we compared 
the negative margins of recurrent and non-recurrent OSCC cases and a P-value of 
0.0041has been obtained which is found to be more significant.  
The results obtained can be due to its antiproliferative activity. Annexin A1 is 
thought to exert its antiproliferative activity via 1) the constitutive activation of the 
Mitogen-Activated Protein Kinases/Extracellular Signal-Regulated Kinases pathway 
(MAPK/ERK), which was linked to its phosphorylation by epidermal growth factor 
(EGF) 2) it acts as a substrate for the EGF receptor tyrosine kinase, thereby inhibiting 
EGF-mediated proliferation. 3) The EGF receptor family of tyrosine kinases plays 
important roles in cell differentiation and proliferation and in cancer development. 
Annexin A1 is thought to have a src-homology 2 (SH2) domains and can bind to the 
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Growth Factor Receptor-Bound 2 (Grb-2) adaptor protein, which is upstream of the 
MAPK pathway68 4) ERK-mediated disruption of the actin cytoskeleton and 
inhibition of cyclin D1, but not by induction of p21cip1/waf1.69 
The other objective of this study is to compare the tumor proper region of 
various grades of OSCC cases. The proportion of patients with moderate Annexin A1 
expression has been found to be higher amongst patients with moderately 
differentiated tumor (Figure-14) (7/10) when compared to those with well 
differentiated tumor (Figure-13) (6/10), which shows intense expression respectively. 
A significant P-value (0.041) is obtained between the two pathological differentiated 
grades of OSCC cases. 
 However, it can be noted that Annexin A1 expression decreased significantly 
as neoplasia progressed. The increasing percentage of negative Annexin A1 staining 
(scored 0 and 1) is paralleled by an increasing severity of neoplasia. The change in 
Annexin A1 staining reflects the extent of epithelial dysplasia, and a significant 
reduction of Annexin A1 expression occurred in well to moderately differentiated 
OSCC. This indicates the potential utility of Annexin A1 testing for the detection of 
neoplasia. These findings have been found to be concurrent with the findings of 
Zhang L et al., 2008. But they have also analyzed the expression of Annexin A1 in 
poorly differentiated OSCC which is not included in this present study.8 
A close association between Annexin A1 expression and tumour cell 
differentiation is observed in our study. Epithelial differentiation status in well 
differentiated squamous cell carcinoma has been distinguished by Annexin A1 
expression in that, even within the same cancer tissue section, the expression of 
Annexin A has been completely lost in areas of poorly differentiated cells but has 
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been observed in areas of well-differentiated tumour cells forming keratinized pearls 
(Figure-13). This result is in accordance with the report of Lee HG et al., 2002.12   
In a study by Zhu WD et al., 2013 it has been found specifically that, a higher 
Annexin A1 expression indicates improved survival. Annexin A1 expression 
correlates with pathologic differentiation grade of biopsy specimens from OSCC 
patients. Patients with low Annexin A1 expression may benefit from wide surgical 
excision or (docetaxel, cisplatin, and 5-fluorouracil) TPF induction chemotherapy 
compared to those with high Annexin A1 expression.1  
 Ki-67 has been shown to be an excellent marker for the estimation of the 
growth fraction in both normal and malignant tissue. Its nuclear expression during a 
defined period of the cell cycle represents an advantage in its use as a biological 
marker of mitotic activity. Also it has a much shorter half life, thus producing less 
residual staining after cells have gone through proliferation stage.42  
We analyzed the positive staining of Ki-67 marker in the negative margins of 
basal and suprabasal layers of the above mentioned 3 groups and a comparison 
between these three groups have been performed using Chi-square test. In normal oral 
mucosa, strong positive Ki-67 staining has been detected in the proliferative layers of 
epithelia (basal and suprabasal) (Figure-16).  
 On analyzing the negative margins of non-recurrent OSCC cases, 2 cases 
show positive expression of 0-25% and 13 cases show 25-50% of positive expression. 
In case of negative margins of recurrent OSCC cases 3 cases show 50-75%, 2 cases 
show 75-100 of positive staining respectively (Figure-19). 
A non-significant P-value of 0.229 has been obtained on comparing the 
normal buccal mucosa with negative margins of non-recurrent OSCC cases. A 
comparison between normal buccal mucosa and negative margins of recurrent OSCC 
 
Discussion 
 
55 
 
cases performed, which gives a highly significant P-value of 0.001. Finally, a 
comparison between the negative margins of recurrent and non-recurrent OSCC cases 
is analyzed and a P-value of <0.0001 has been obtained which is found to be more 
significant. These results are based upon the intranuclear positive expression of Ki-67 
antibody. 
On examining the intranuclear expression in the tumor proper region of well 
differentiated OSCC, 1 case shows mild expression, 7 cases show moderate 
expression and 2 cases show intense expression (Figure-17). In case of moderately 
differentiated OSCC, 4 cases show moderate expression and 6 cases show intense 
expression respectively (Figure- 18). A comparison is made and a significant P-value 
(0.041) has been obtained between the two pathological differentiated grades of 
OSCC cases.   
It has been noted that in a study by Birajdar SS et al., 2014 Ki-67 positive cells 
in well differentiated OSCC have been  found to be located in the periphery of the 
tumor nests where frequent mitoses has been observed than the central areas of 
squamous maturation which suggest that less differentiated cells have been found to 
be located in the peripheral layer and the central cells are highly differentiated with an 
ability to keratinize, thus no expression of Ki-67 has been observed in the central cells 
of tumor island (Figure-17).42 This result is similar the result of our present study. 
It has also been observed that, in moderately differentiated OSCC, Ki-67 
expression was seen in both peripheral and part of central layer, as cells were less 
differentiated than well differentiated OSCC. This finding correlate with the result of 
the study done by Ronald et al., 1994.70 
Wangsa D et al., 2008 in their study have shown that Ki-67 expression level is 
a potentially useful clinical marker for predicting recurrence in surgically treated 
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stage I oral tongue SCC. 71 Motta et al., 2009 have proven that Ki-67 expression is 
significantly higher in oral epidermoid carcinoma patients with neck lymph node 
metastasis.72 
High-proliferative activity is related to an elevated recurrence risk after 
surgery in patients with stage I tumours, making Ki-67 a potentially useful marker for 
patients in need of more extensive treatment (i.e. surgery with more extensive 
margins, neck dissection and postoperative radiotherapy). The high rate of metastasis 
in stages I and II tumours is in accordance with previous studies that show a failure 
rate at 20–40% (Sano and Myers., 2007).62 
 Earlier studies on Ki-67 expression in locoregional recurring oral cancers 
revealed conflicting results. Two studies have suggested that a Ki-67 labelling index 
of more than 20% was associated with a significantly worse locoregional control 
(56%) in oropharyngeal cancer (Grabenbauer et al., 2000, Wilson et al., 2006).73, 74 
This is in agreement with our results that found that high-proliferative activity is 
associated with an elevated risk for recurrence. 
 This is because Ki-67 is a nuclear protein attaching to nuclear antigens 
expressed in phases of the proliferation except G0, and it serves as one of the major 
factors related to tumor proliferation and was strongly associated with the 
aggressiveness of tumor. 75 
Although the Ki-67 protein is well characterized on the molecular level and 
extensively used as a proliferation marker, the functional significance still remains 
unclear. There are indications, however, that Ki-67 protein expression is an absolute 
requirement for progression through the cell division cycle.75   
 Thus from our study results, local recurrence can be predicted with the usage 
of Annexin A1 and Ki-67 markers. 
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SUMMARY 
Annexin A1 and Ki-67 protein expression is studied using mouse polyclonal 
Annexin A1 antibody and mouse monoclonal Ki-67 antibody in the tumor proper 
region and histopathologically negative margins of well and moderately differentiated 
OSCC cases with and without local recurrence.  Paraffin embedded lesional tissues 
are obtained from the achieves   of the Department of Oral and Maxillofacial 
Pathology.  
The immunohistochemical procedure is carried out using polyclonal Annexin 
A1 (ABCAM) and monoclonal Ki-67 antibody (DAKO), both raised against mouse. 
The immunohistochemical secondary antibody (DAKO) is used. Both antibodies are 
used according to manufacturers’ instructions. Antigen unmasking is performed by 
pressure cooker antigen retrieval method.  
Intense staining in human endometrium tissue served as positive control for 
Annexin A1 and neural tissue served as positive control for Ki-67. Only cells with 
Annexin A1and Ki-67 expression are considered positive. The staining intensity is 
graded as mild, moderate and intense.  
From the study the following observations are made: 
Observations based on expression of Annexin A1 
1) In normal buccal mucosa, strong positive Annexin A1 staining is detected in the 
differentiated and non-proliferating squamous cells, with negative staining in the 
proliferative layers of epithelia (basal and suprabasal). 
2) On analyzing the negative margins of non-recurrent OSCC cases, 11 cases show 
negative staining of 0-25% and 4 cases show 25-50%. In case of negative 
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margins of recurrent OSCC cases 1 case show 25-50%, 2 cases show 50-75% 
and 2 cases show 75-50% of negative staining respectively. 
3) A highly significant P-value of 0.002 is obtained on comparing the normal 
buccal mucosa with negative margins of non-recurrent OSCC cases.  
4) On comparison between normal buccal mucosa and negative margins of 
recurrent OSCC cases, P-value of 0.012 is obtained.  
5) On final comparison of negative margins of recurrent and non-recurrent OSCC 
cases, a P-value of 0.0041 is obtained which is found to be more significant. 
6) On analyzing the tumor proper region between the pathologically differentiated 
grades of OSCC cases a significant P-value (0.041) is obtained. Annexin A1 
expression decreased significantly as neoplasia progressed in OSCC cases. 
7) In well differentiated OSCC, the expression of Annexin A has been completely 
lost in areas of poorly differentiated cells but has been observed in areas of well-
differentiated tumor cells forming keratinized pearls. 
 Observations based on expression of Ki-67 
8) In normal oral mucosa, strong positive Ki-67 staining is detected in the 
proliferative layers of epithelia (basal and suprabasal). 
9) On analyzing the negative margins of non-recurrent OSCC cases, 2 cases show 
positive expression of 0-25% and 13 cases show 25-50% of positive expression. 
In case of negative margins of recurrent OSCC cases 3 cases show 50-75%, 2 
cases show 75-100 of positive staining respectively. 
10) On comparing the normal buccal mucosa with negative margins of non-recurrent 
OSCC cases a non-significant P-value of 0.229 is obtained. 
11) A comparision between normal buccal mucosa and negative margins of recurrent 
OSCC cases is performed, which gives a highly significant P-value of 0.001. 
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12) On final comparision between the negative margins of recurrent and non-
recurrent OSCC cases a P-value of <0.0001 is obtained which is found to be 
more significant. 
13)  A significant P-value (0.041) is obtained between the pathological differentiated 
grades of OSCC. Expression of Ki-67 increased significantly as neoplasia 
progressed in OSCC cases. 
14) Ki-67 positive cells in well differentiated OSCC have been found to be located 
in the periphery of the tumor nests. No expression has been observed in the 
central cells of tumor island. 
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CONCLUSION 
To conclude, anti-proliferative activity of Annexin A1 and proliferative 
activity of the Ki-67 nuclear antigen has been linked and investigated whether their 
expression can be of clinical use for prediction of locoregional recurrence exclusively 
in primary OSCC. The results of this study provide data on Annexin A1 and Ki-67 
expression in the tumor proper region and histopathologically negative margins of 
well and moderately differentiated OSCC cases with and without LR. Thus by 
predicting the LR, surgeons can be intimated for wide local excision, thereby 
preventing treatment failures and benefiting the patients. Owing to limited sample size 
and lesser number of recurrent OSCC cases (because LR refers to recurrence of the 
lesion within the period of 3 years and cases with complete history needs to be 
considered) the significance of our findings have to be confirmed with a larger sample 
size.   
 
   
   
   
 
References 
 
REFERENCES 
1) Zhu D, Liu Y, Yang X, Yang C, Ma J, Yang X, et al. Low Annexin A1 expression 
predicts benefit from induction chemotherapy in oral cancer patients with 
moderate or poor pathologic differentiation grade. BMC Cancer 2013; 13(2): 301-
10. 
2) Braakhuis BJ, Tabor MP, Leemans CR, van der Waal, Snow GB, Brakenhoff RH. 
Second primary tumors and field cancerization in oral and oropharyngeal cancer: 
molecular techniques provide new insights and definitions. Head Neck 2002; 
24(3): 198–206. 
3) Leemans CR, Tiwari R, Nauta JJ, Vander Waal I, Snow GB. Recurrence at the 
primary site in head and neck cancer and the significance of neck lymphnode 
metastases as a prognostic factor. Ancer 1994; 73(5): 187-90. 
4) Wang X, Chen S, Chen X, Zhang C, Liang X. Tumor-related markers in 
histologically normal margins correlate with locally recurrent oral squamous cell 
carcinoma: a retrospective study. J Oral Pathol Med 2015; 45(2): 83-88. 
5) Zhu DW, Yang X, Yang CZ, Ma J, Liu Y, Yan M. Annexin A1 down-regulation 
in oral squamous cell carcinoma correlates to pathological differentiation 
grade. Oral Oncol 2013; 49(6): 542-60.  
6) Premalatha BR, Uma K. Analysis of KI-67 in human Oral Squamous Cell 
Carcinoma – An immunohistochemical study. J Int Oral Health 2010; 2(1): 9-16. 
7) Lim H, Pervaiz S. Annexin 1: The new face of an old molecule. FASEB J 2007; 
21(4): 968-75. 
 
References 
 
8) Zhang L, Wang LD, Yang Y, Liu Y, Li LP, Xhou JX et al. Decreased Expression 
of Annexin A1 during the Progression of Cervical Neoplasia. J Int Med Res 2008; 
36(4): 665-72. 
9) Endl E, Gerdes J. The Ki-67 Protein: Fascinating Forms and an Unknown 
Function. Exp Cell Res 2000; 257(2): 231-7. 
10) Walter C, Festa M, Gbelcova H et al. The complex understanding of Annexin A1 
phosphorylation. Cell Signal 2014; 26(1): 173-78. 
11) Jerke V, Moss SV. Annexins: From Structure to Function. Physiol Rev 2002; 
82(1): 1-41. 
12) Lee HC, Yen YC, Liu SY, Chen CK, Chiang FC. Axl Is a Prognostic Marker in 
Oral Squamous Cell Carcinoma. Ann Surg Oncol 2012; 19(3): 503-08. 
13) Sugimato AM, Vago PJ, Teixeria M, Sousa PL. Annexin A1 and the Resolution of 
Inflammation: Modulation of Neutrophil Recruitment, Apoptosis, and 
Clearance. J Inflamm Res 2016; 14(3): 1-13. 
14) Donohue PM, Bartolotti JL, Yumin LI. The N-terminal of Annexin A1 as a 
Secondary Membrane Binding Site: A Molecular Dynamics Study. Proteins: 
Struct, Funct, Bioinf 2014; 82(11): 111-15. 
15) Hu, Jen N, Bradshaw, Jeremy, Lauter, Hans J et al. Membrane-Induced Folding 
and Structure of Membrane-Bound Annexin A1 N-Terminal Peptides: 
Implications for Annexin-Induced Membrane Aggregation. Biophys J 2008; 
94(13): 1173-81. 
16) Wang LP, Bi J, Yao C, Chang QG, Shen K. Annexin A1 expression and its 
prognostic significance in human breast cancer. Neoplasma 2010; 57(3): 253-9. 
 
References 
 
17) Yom CK, Han W, Kim SW, Kim HS, Shin HC, Chang JN et al. Clinical 
significance of annexin A1 expression in breast cancer. J Breast Cancer 2011; 
14(4): 262-8. 
18) Leite SM, Smith BM, Wesseling J, Blows MF. Annexin A1 expression in a 
pooled breast cancer series: association with tumor subtypes and prognosis. BMC 
Med 2015; 13(3): 156-9. 
19) Bai FX, Ni XG, Zhao P, Zhao HX. Overexpression of annexin 1 in pancreatic 
cancer and its clinical significance. World J Gasteroenterol 2004; 10(10): 1466-
70. 
20) Bedvedere R, Bizzarro V, Forte G, Piaz DF, Parente L. Annexin A1 contributes to 
pancreatic cancer cell phenotype, behaviour and metastatic potential 
independently of Formyl Peptide Receptor pathway. Sci Rep 2016; 11(3): 11-15. 
21) Han G, Tian Y, Duan B, Sheng H, Gao H, Huang J et al. Association of nuclear 
annexin A1 with prognosis of patients with esophageal squamous cell 
carcinoma. Int J Clin Exp Pathol 2014; 7(2): 751-59. 
22) Wang LK, Wu TT, Wang H, Wayne L, Rashid A, Hamilton RS. Expression of 
annexin A1 in esophageal and esophagogastric junction adenocarcinomas: 
Association with poor outcome. Clin Cancer Res 2006; 12(15): 4598-604. 
23) Huang H, Yan LX, Peng W. Expression of annexin a1 in tumorigenesis of 
esophageal squamous cell carcinoma. CJCR 2004; 16(1): 20-23. 
24) Nomura H, Uzawa K, Yamano Y, Fushimi K, Nakashima D, Kouzu Y, et al. 
Down-regulation of plasma membranous Annexin A1 protein expression in 
premalignant and malignant lesions of the oral cavity: correlation with epithelial 
differentiation. J Cancer Res Clin Oncol 2009; 135: 943-5. 
 
References 
 
25) Lin CY, Jeng YM, Chou HY, Hsu HC, Yuan RH, Chiang CP, Kuo MY. Nuclear 
localization of Annexin A1 is a prognostic factor in oral squamous cell carcinoma. 
J Surg Oncol 2008; 97(6): 544-50. 
26) Zhang L, Yang X, Zhong PL, Hou JX, Pan H, Li J et al. Decreased expression of 
Annexin A1 correlates with pathologic differentiation grade in oral squamous cell 
carcinoma. J Oral Pathol Med 2009; 38(3): 362-70. 
27) Endl E, Jerdes J. The Ki-67 Protein: Fascinating Forms and an Unknown 
Function. Science Direct 2000; 257(2): 231-37. 
28) Patel MS, Patel AK, Patel RP, Gamit B, Hathila NR, Gupta S. Expression of p53 
and ki-67 in oral dysplasia and squamous cell carcinoma: an 
immunohistochemical study. IJMSPH 2014; 4(10): 1201-04. 
29) Sobecki M, Mrouj K, Cammasses A, Parisis N, Nicolas E, Gerbe F et al. The cell 
proliferation antigen Ki-67 organises heterochromatin. Cell Biol 2016; 5(2): 1-33. 
30) Shatseva TA, Muhina MS. Role of Ki-67 antigen in tumor proliferation--its 
structure and functions. Vopr Onkol 2004; 50(2): 157-64. 
31) Ermiah E, Buhmeida A, Abdalla F, Khaled RB, Salem N, Collan Y et al. 
Prognostic Value of Proliferation Markers: Immunohistochemical Ki-67 
Expression and Cytometric S-Phase Fraction of Women with Breast Cancer in 
Libya. Jcancer 2012; 3(2): 421-31. 
32) Mohammed A A, Rakha AE, Macmillan D, Powe DG, Ellis OI, Green RA et al. 
MIB1/Ki-67 labelling index can classify grade 2 breast cancer into two clinically 
distinct subgroups. Breast Cancer Res Treat 2011; 127(3): 591-99. 
33) Velappan A, Shanmugam D. Evaluation of Ki-67 in Breast Cancer. IOSR-
JDMS 2017; 16(3): 55-64. 
 
References 
 
34) Hamilton AN, Liu CT, Cavatio A, Mawad K, Chen L, Cao D et al. Ki-67 Predicts 
Disease Recurrence and Poor Prognosis in Pancreatic Neuroendocrine 
Tumors. Surgery 2012; 152(1): 107-13. 
35) Call MC, Chad M, Shi C, Toby C, David S, Laura H et al. Grading of Well-
differentiated Pancreatic Neuroendocrine Tumors Is Improved by the Inclusion of 
Both Ki67 Proliferative Index and Mitotic Rate. Am J Surg Pathol 2013; 37(11): 
1671-77. 
36) Linder S, Parroda C, Falkmer UG, Blasjo M, Sundelin P, Von A. Prognostic 
significance of Ki-67 antigen and p53 protein expression in pancreatic duct 
carcinoma. Br J Cancer 1997; 76(1): 54-9. 
37) Sasagava H, Shiosaki A, Litaka D, Ichikava D, Komatsu S, Fujiwara H et al. Ki-
67 labeling index as an independent prognostic factor in human esophageal 
squamous cell carcinoma. Esophagus 2012; 9(4): 195-202. 
38) Bellini FM, Cury PM, Silva EA. Expression of Ki-67 Antigen and Caspase-3 
Protein in Benign Lesions and Esophageal Carcinoma. Cancer Res Treat 2010; 
30(7): 2845-48. 
39) Hong K, Laskin BW, Herman EB, Johnston HM, Vargo JJ, Allegra CJ. Expansion 
of the Ki-67 proliferative compartment correlates with degree of Dysplasia in 
esophagal carcinoma. Cancer 1995; 75(3): 423-9. 
40) Amrani HJ, Marchoudi N, Haddad F, Fechtali T, Benomar H, Elgnaouil H. Ki-67 
Expression in Gastric Cancer and Correlation with Clinico-Pathological 
Characteristics. IJSRP 2014; 4(6): 1-4. 
41) Humayun S, Prasad RV. Expression of p53 protein and ki-67 antigen in oral 
premalignant lesions and oral squamous cell carcinomas: An 
immunohistochemical study. Natl J Maxillofac Surg 2011; 2(1): 38-46. 
 
References 
 
42) Birajdar SS, Radhika MB, Paremala K, Sudhakara M, Soumya M, Gadivan M. 
Expression of Ki-67 in normal oral epithelium, leukoplakic oral epithelium and 
oral squamous cell carcinoma. JOMFP 2014; 18(2): 169-76. 
43) Maheswari V, Sharma SC, Narula V, Verma S, Jain A, Alam K. Prognostic and 
predictive impact of Ki-67 in premalignant and malignant squamous cell lesions 
of oral cavity. IJHNS 2013; 4(2): 61-65. 
44) Priya K, Kane S, Rathod PG. Coexpression of p53 and Ki 67 and lack of c-erbB2 
expression in oral leukoplakias in India. Braz Oral Res 2012; 26(3): 228-34. 
45) Patel MS, Gamit B, Hathila MR, Gupta S, Patel RP, Patel AK. Expression of p53 
and ki-67 in oral dysplasia and squamous cell carcinoma: an 
immunohistochemical study. Int J Med Sci 2014; 3(10): 1201-04. 
46) Angiero F, Berenzi A, Bennetti A, Rossi E, Sidoni A, Dessy E et al. Expression of 
p16, p53 and Ki-67 proteins in the progression of epithelial dysplasia of the oral 
cavity. Anticancer Res 2008; 28(5): 2535-9. 
47) Dwivedi N, Chandra S, Kashyap B, Raj V, Agarwal A. Suprabasal expression of 
Ki-67 as a marker for the severity of oral epithelial dysplasia and oral squamous 
cell carcinoma. Contemp Clin Dent 2013; 4(1): 7-12. 
48)  Raju B, Mehrotra R, Gunnvar J, Ibrahim OS. Expression of p53, cyclin D1 and 
Ki-67 in pre-malignant and malignant oral lesions: Association with 
clinicopathological parameters. Anticancer Res 2005; 25(6C): 4699-706. 
49) Roy S, Rendon TA, Craig GT, Speight PM. Expression of Mcm2, geminin and 
Ki67 in normal oral mucosa, oral epithelial dysplasias and their corresponding 
squamous-cell carcinomas. Br J Cancer 2009; 100(7): 1128-34. 
50) Freir K, Hoffmann J, Engel J. Ki-67 expression predicts radiosensitivity in oral 
squamous cell carcinoma. IJMFS 2012; 41(8): 965-9. 
 
References 
 
51) Warnakulasuriya S, Dissanayake U, Johnson N. Comparison of cell proliferation 
in the centre and advancing fronts of oral squamous cell carcinomas using Ki-67 
index. Cell Proliferat 2003; 36(5): 255-64. 
52) Sassi LM, Loshii SO, Oliveira BV, Pedruzzi PA, Guebur M, Schussel J L et al. 
Second Primary Tumor: P53 and Ki-67 Expression in Patients with Oral 
Squamous Cell Carcinoma. Int J Cancer 2011; 3(2): 2-8. 
53) Xie S, Liu Y, Qioa X, Hua XR, Wang K, Feng X. What is the Prognostic 
Significance of Ki-67 Positivity in Oral Squamous Cell Carcinoma?. J 
Cancer 2016; 7(7): 758-67. 
54) Moles GMA, Avila R, Montoyo G, Esteban F, Bravo M. Analysis of Ki-67 
expression in oral squamous cell carcinoma: Why Ki-67 is not a prognostic 
indicator. Oral Oncol 2010; 46(7): 525-30. 
55) Tumuluri V, Thomas GA, Fraser IS. Analysis of the Ki-67 antigen at the invasive 
tumour front of human oral squamous cell carcinoma. J Oral Pathol Med. 2002; 
31(1):598-604. 
56) Cortegoso A, Laureano N, Silva A, Danilevickz A, Rados P, Visioli F et al. Cell 
proliferation markers at the invasive tumor front of oral squamous cell carcinoma: 
comparative analysis in relation to clinicopathological parameters of patients. J 
Appl Oral Sci 2016; 25(3): 11-15. 
57) Bànkfalvi A, Piffkò J. Prognostic and predictive factors in oral cancer: the role of 
the invasive tumour front. J Oral Pathol Med. 2000; 29(3): 291-8. 
58) Bryne M. Is the invasive front of an oral carcinoma the most important area for 
prognostication? Oral Dis. 1998; 4(1): 70-7.  
 
References 
 
59) Kurokawa H, Zhang M, Matsumoto S, Yamashita Y, Tomoyose T, Tanaka T, et 
al. The high prognostic value of the histologic grade at the deep invasive front of 
tongue squamous cell carcinoma. J Oral Pathol Med. 2005; 34(4): 329-33.  
60) Pereira CH, Morais MO, Martins AF, Soares MQ, Alencar RC, Batista AC, et al. 
Expression of adhesion proteins (E-cadherin and β-catenin) and cell proliferation 
(Ki-67) at the invasive tumor front in conventional oral squamous cell and 
basaloid squamous cell carcinomas. Arch Oral Biol. 2016; 61(3): 8-15. 
61) Kessler P, Poort L, Bloebaum M, Bockmann R. Survival after curative surgical 
treatment for primary oral squamous cell carcinoma. J Craniomaxillofac 
Surg 2014; 42(8): 1572-76. 
62) Myers NJ, Sano D. Metastasis of squamous cell carcinoma of the oral 
tongue. Cancer Metastasis Rev 2007; 26(3): 645-62. 
63)  Binahmed A, Nason RW, Abdoh AA. The clinical significance of the positive 
surgical margin in oral cancer. Oral Oncol 2007; 43(3): 780–4. 
64) Sutton DN, Brown JS, Rogers SN, Vaughan ED, Woolgar JA. The prognostic 
implications of the surgical margin in oral squamous cell carcinoma. Int J Oral 
Maxillofac Surg 2003; 32(1): 30–4. 
65) Houten VM, Leemans CR, Kummer JA. Molecular diagnosis of surgical margins 
and local recurrence in head and neck cancer patients: a prospective study. Clin 
Cancer Res 2004; 10(2): 3614–20. 
66) Reis PP, Waldron L, Perez-Ordonez B. A gene signature in histologically normal 
surgical margins is predictive of oral carcinoma recurrence. BMC Cancer 2011; 
11(2): 437–48. 
67) Ha PK, Califano JA. The molecular biology of mucosal field cancerization of the 
head and neck. Crit Rev Oral Biol Med 2003; 14(4): 363–36. 
 
References 
 
68) Alldridge LC, Harris HJ, Plevin R, Hannon, R, Bryant CE. The annexin protein 
lipocortin 1 regulates the MAPK/ERK pathway. J Biol Chem 1999; 14(2): 620–
28. 
69) Bitto E, Li M, Tikhonov AM., Schlossman ML, Cho W. Mechanism of annexin I-
mediated membrane aggregation. Biochemistry 2000; 12(4): 469–77. 
70) Ronald NJ, Caslin AW, Bowie GL, Jones AS. Has the cellular proliferation 
marker Ki-67 any clinical relevance in squamous cell carcinoma of the head and 
neck? Clin Otolaryngol Allied Sci. 1994; 19(3):13-8. 
71) Wangsa D, Ryott M, Lundqvist AE, Wikland ME. Ki-67 expression predicts 
locoregional recurrence in stage I oral tongue carcinoma. Brit J Cancer 2008; 
99(7): 1121-8. 
72) Motta RDR, Zettler C, Cambruzzi E, Berni BR. Ki-67 and p53 correlation 
prognostic value in squamous cell carcinomas of the oral cavity and tongue. Braz 
J Otorhinolaryngol 2009; 75(4): 544-9. 
73) Grabenbauer GG, Muhlfriedel C, Rodel F, Niedobitek G, Hornung J, Rodel C, et 
al. Squamous cell carcinoma of the oropharynx: Ki-67 and p53 can identify 
patients at high risk for local recurrence after surgery and postoperative 
radiotherapy. Int J Radiat Oncol Biol Phys. 2000; 48(13):1041–50. 
74) Wilson GD, Saunders MI, Dische S, Daley FM, Buffa FM, Richman PI, Bentzen 
SM. Pre-treatment proliferation and the outcome of conventional and accelerated 
radiotherapy. Eur J Cancer. 2006; 42(11):363–71. 
75) Scholzen T, Jerdes J. The Ki-67 protein: From the known and the unknown. J Cell 
Physiol 182:311–322, 2000; 182: 311-22. 
 
 
 
References 
 
76) Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. 
Immunohistochemical Detection of  EGFR in Paraffin-embedded Tumor Tissues; 
Variation in Staining Intensity due to choice of Fixative and Storage Time of 
Tissue Sections. Journal of Histochemistry & Cytochemistry 2004; 52(7): 893-
901. 
 
ANNEXURE-1 
  Annexin A1 expression in well differentiated OSCC 
S. No. 
Percentage of intranuclear 
expression of Annexin A1 
Percentage of intracytoplasmic 
expression of Annexin A1 
 Field I Field  II Field III % Field I 
 
Field II 
 
Field III % 
01 
41% 48% 39% 
42.6% 
92% 
88% 91% 90.3% 
02 14% 18% 16% 16% 80% 82% 87% 83% 
03 34% 41% 38% 37.6% 91% 93% 84% 91.6% 
04 14% 10% 12% 12% 93% 92% 90% 91.6% 
05 08% 06% 11% 8.3% 86% 80% 82% 82.6% 
06 19% 15% 21% 18.3% 90% 85% 87% 87.3% 
07 13% 19% 17% 16.3% 92% 90% 90% 90.6% 
08 15% 17% 22% 18% 89% 86% 86% 87% 
09 08% 11% 06% 8.3% 86% 84% 82% 84% 
10 12% 18% 15% 15% 90% 81% 87% 86% 
 
 
 
 
 
ANNEXURE-2 
Annexin A1 expression in moderately differentiated OSCC 
S. No. 
Percentage of intranuclear 
expression of Annexin A1 
Percentage of intracytoplasmic 
expression of Annexin A1 
 Field I Field  II Field III % Field I 
Field II 
 
Field III % 
01 6% 5% 8% 6.3% 77% 70% 68% 71.6% 
02 8% 9% 6% 7.6% 69% 66% 74% 69.6% 
03 3% 4% 7% 4.6% 76% 72% 64% 70.6% 
04 9% 8% 9% 8.6% 71% 68% 75% 71.3% 
05 7% 5% 6% 6% 60% 66% 62% 62.6% 
06 8% 7% 10% 8.3% 73% 75% 77% 75% 
07 4% 2% 4% 3.3% 55% 60% 63% 59.3% 
08 5% 4% 7% 5.3% 50% 54% 55% 53% 
09 6% 9% 7% 7.3% 70% 74% 71% 71.6% 
10 7% 6% 5% 6% 74% 75% 64% 71% 
 
 
 
 
 
 
 
ANNEXURE-3 
 Annexin A1 expression in normal buccal mucosa   
S. No. Negative  expression of Annexin A1 
Annexin A1 positivity in both basal 
& parabasal layer of epithelium 
 Field I Field  II Field III % Field I 
 
Field II 
 
Field III % 
01 45% 54% 48% 49% 55% 46% 52% 51% 
02 42% 44% 50% 45.3% 58% 56% 50% 54% 
03 39% 41% 40% 40% 61% 59% 60% 60% 
04 44% 52% 42% 46% 56% 48% 54% 52.6% 
05 31% 35% 30% 32.3% 69% 65% 70% 68% 
06 40% 43% 39% 40.6% 60% 57% 61% 59.3% 
07 29% 30% 27% 28.6% 71% 70% 73% 71.3% 
08 45% 42% 51% 46% 55% 58% 49% 54% 
09 32% 28% 37% 32.3% 68% 72% 63% 67.6% 
10 22% 27% 21% 23.3% 78% 73% 79% 76.6% 
 
 
 
 
 
 
 
ANNEXURE-4 
Annexin A1 exprssion in the negative margins of non- recurrent OSCC 
S. No. Negative expression of Annexin A1 
Annexin A1 positivity in both basal 
& parabasal layer of epithelium 
 Field I Field  II Field III % Field I 
 
Field II 
 
Field III % 
01 22% 26% 29% 25.6% 78% 74% 71% 74.3% 
02 22% 24% 16% 20.6% 78% 76% 84% 79.3% 
03 15% 18% 20% 17.6% 85% 82% 80% 82.3% 
04 25% 26% 22% 24.3% 75% 74% 78% 75.6% 
05 16% 14% 17% 15.6% 84% 86% 83% 84.3% 
06 21% 22% 25% 22.6% 79% 78% 75% 77.3% 
07 23% 25% 28% 25.3% 77% 75% 72% 74.6% 
08 30% 29% 33% 30.6% 70% 71% 67% 69.3% 
09 18% 15% 20% 17.6% 82% 85% 80% 82.3% 
10 16% 19% 17% 17.3% 84% 81% 83% 82.6% 
11 31% 28% 33% 30.6% 69% 72% 67% 69.3% 
12 11% 18% 16% 15% 89% 82% 84% 85% 
13 22% 27% 25% 24.6% 78% 73% 75% 75.3% 
14 16% 18% 14% 16% 84% 82% 86% 84% 
15 15% 13% 17% 15% 85% 87% 83% 85% 
 
 
 
ANNEXURE-5 
Annexin A1 expression in the negative margins of recurrent OSCC 
S. No Negative expression of Annexin A1 
Annexin A1 positivity in both basal 
& parabasal layer of epithelium 
 Field I Field  II Field III % Field I 
 
Field II 
 
Field III % 
01 75% 72% 79% 75.3% 25% 28% 21% 24.6% 
02 62% 67% 58% 62.3% 38% 33% 42% 37.6% 
03 86% 79% 82% 82.3% 14% 21% 18% 17.6% 
04 71% 61% 68% 66.6% 29% 39% 32% 33.3% 
05 45% 53% 49% 49% 55% 47% 51% 51% 
 
 
 
 
 
 
 
 
 
 
ANNEXURE-6 
Ki-67 expression in well differentiated OSCC 
S. No. Percentage of intranuclear expression of KI-67 
 Field I Field  II Field III % 
01 31% 35% 28% 31.3% 
02 36% 32% 38% 35.3% 
03 9% 12% 8% 9.6% 
04 31% 36% 29% 32% 
05 10% 16% 13% 13% 
06 15% 19% 12% 15.3% 
07 11% 16% 10% 12.3% 
08 12% 18% 11% 13.6% 
09 8% 13% 12% 11% 
10 19% 23% 18% 20% 
 
 
 
 
 
 
 
 
ANNEXURE-7 
Ki-67 expression in moderately differentiated OSCC 
S. No. Percentage of intranuclear expression of  KI-67 
 Field I Field  II Field III % 
01 
66% 
54% 52% 57.3% 
02 32% 28% 36% 32% 
03 12% 19% 15% 15.3% 
04 47% 42% 40% 43% 
05 58% 54% 48% 53.3% 
06 27% 32% 25% 28% 
07 39% 42% 36% 39% 
08 29% 28% 31% 29.3% 
09 37% 32% 30% 33% 
10 45% 36% 42% 41% 
 
 
 
 
 
ANNEXURE-8 
Ki-67 expression in normal buccal mucosa 
S. No. Negative  expression of Ki-67 
Ki-67 positivity in both basal & 
parabasal layer of epithelium 
 Field I Field  II Field III % Field I 
 
Field II 
 
Field III % 
01 58% 52% 50% 53.3% 42% 48% 50% 46.6% 
02 53% 56% 51% 53.3% 47% 44% 49% 46.6% 
03 60% 62% 64% 62% 40% 38% 36% 38% 
04 66% 59% 63% 62.6% 34% 41% 37% 37.3% 
05 62% 58% 60% 60% 38% 42% 40% 40% 
06 61% 63% 59% 61% 39% 37% 41% 39% 
07 70% 65% 68% 67.6% 30% 35% 32% 32.3% 
08 57% 48% 54% 53% 43% 52% 46% 47% 
09 70% 63% 67% 66.6% 30% 37% 33% 33.3% 
10 68% 67% 65% 66.6% 32% 33% 35% 33.3% 
 
 
 
 
 
 
ANNEXURE-9 
Ki-67 expression in the negative margins of recurrent OSCC 
S. No. Negative  expression of Ki-67 
Ki-67 positivity in both basal & 
parabasal layer of epithelium 
 Field I Field  II Field III % Field I 
 
Field II 
 
Field III % 
01 61% 67% 65% 64.3% 39% 33% 35% 35.6% 
02 67% 64% 63% 64.6% 33% 36% 37% 35.3% 
03 76% 78% 72% 75.3% 24% 22% 28% 24.6% 
04 55% 53% 52% 53.3% 45% 47% 48% 46.6% 
05 61% 56% 57% 58% 39% 44% 43% 42% 
06 78% 76% 72% 75.3% 22% 24% 28% 24.6% 
07 63% 61% 60% 61.3% 37% 39% 40% 38.6% 
08 62% 56% 57% 58.3% 38% 44% 43% 41.6% 
09 57% 60% 54% 57% 43% 40% 46% 43% 
10 60% 57% 54% 57% 40% 43% 46% 43% 
11 79% 72% 73% 74.6% 21% 28% 27% 25.3% 
12 66% 64% 62% 64% 34% 36% 38% 36% 
13 58% 59% 53% 56.6% 42% 41% 47% 43.3% 
14 64% 62% 67% 64.3% 36% 38% 33% 35.6% 
15 68% 65% 62% 65% 32% 35% 38% 35% 
 
 
 
ANNEXURE-10 
Ki-67 expression in the negative margins of recurrent OSCC 
S.No. Negative  expression of Ki-67 
Ki-67  positivity in both basal & 
parabasal layer of epithelium 
 Field I Field  II Field III % Field I 
 
Field II 
 
Field III % 
01 24% 22% 20% 27.3% 76% 78% 80% 78% 
02 29% 34% 33% 32% 71% 66% 64% 67% 
03 14% 17% 12% 14.3% 86% 83% 88% 85.6% 
04 32% 28% 36% 32% 68% 72% 64% 68% 
05 42% 33% 37% 37.3% 58% 67% 63% 62.6% 
 
 
  
 
 
 
 
 
 
